Core Insights - Belite Bio announced successful topline results from the Phase 3 "DRAGON" trial of Tinlarebant, the first pivotal trial for treating Stargardt disease type 1 (STGD1), which currently has no approved treatments globally [1][3] Trial Results - The DRAGON trial enrolled 104 patients and met its primary efficacy endpoint, showing a statistically significant 36% reduction in the growth rate of retinal lesions compared to placebo, with a p-value of 0.0033 [2][6] - A post-hoc analysis indicated a consistent treatment effect with a p-value of <0.0001, reinforcing the efficacy of Tinlarebant [2][6] - The treatment also demonstrated a significant reduction in lesion growth in the fellow eye, with a 33.6% reduction (p = 0.041) [13] Safety Profile - Tinlarebant was well tolerated throughout the trial, with only four treatment-related discontinuations reported [6][20] - The safety profile was consistent with previous trials, with mild ocular adverse events such as xanthopsia and delayed dark adaptation [20] Regulatory Plans - Belite Bio plans to file a New Drug Application (NDA) with the US FDA in the first half of 2026 [6][9] - The drug has received multiple designations including Breakthrough Therapy and Orphan Drug Designation in the U.S., Europe, and Japan [9][17] Company Overview - Belite Bio is focused on developing novel therapeutics for degenerative retinal diseases, with Tinlarebant as its lead candidate [18] - The company is also evaluating Tinlarebant in ongoing trials for other retinal conditions, indicating a commitment to addressing significant unmet medical needs [18]

Core Insights - Belite Bio, Inc. has received acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for a Conditional Marketing Authorization application for Tinlarebant, aimed at treating Stargardt disease based on interim analysis results from the Phase 3 DRAGON trial [1][3][8] Company Overview - Belite Bio is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease and geographic atrophy in advanced dry age-related macular degeneration [6] - The lead candidate, Tinlarebant, is an oral therapy designed to reduce the accumulation of vitamin A-based toxins in the eye, which are implicated in retinal diseases [5][6] Clinical Trial Details - The Phase 3 DRAGON trial is a randomized, double-masked, placebo-controlled study evaluating the safety and efficacy of Tinlarebant in 104 adolescent patients with Stargardt disease across 11 jurisdictions [4] - The primary efficacy endpoint of the trial is the growth rate of atrophic lesions, alongside safety and tolerability assessments [4] Regulatory Progress - The interim analysis results from the DRAGON trial met the criteria for the Conditional Marketing Authorization application, with final topline data expected to be reported in Q4 2025 [3][8] - The company is optimistic about the global submissions and potential approvals based on consistent feedback from major regulatory agencies [2]